RBTT-03. A PHASE 1, MULTICENTER, RANDOMIZED, OPEN-LABEL, PERIOPERATIVE STUDY OF AG-120 (IVOSIDENIB) AND AG-881 IN PATIENTS WITH RECURRENT, NONENHANCING, IDH1-MUTANT, LOW-GRADE GLIOMA

Mutations in isocitrate dehydrogenase (mIDH) are common in lower-grade glioma (LGG; mIDH1, 80%; mIDH2, 4%) and lead to epigenetic and genetic changes that promote oncogenesis via production of the oncometabolite 2-hydroxyglutarate (2-HG). AG-120 (ivosidenib) is a first-in-class oral mIDH1 inhibitor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Neuro Oncol
Main Authors: Mellinghoff, Ingo, Maher, Elizabeth, Wen, Patrick, Cloughesy, Timothy, Peters, Katherine, Choi, Changho, Ellingson, Benjamin, Lin, Alexander, Li, Yan, Soher, Brian, Young, Robert, Steelman, Lori, Le, Kha, Yin, Feng, Wu, Bin, Lu, Min, Zhang, Yanwei, Nicolay, Brandon, Schoenfeld, Steven, Yen, Katharine, Pandya, Shuchi, Clarke, Jennifer
Formato: Artigo
Idioma:Inglês
Publicado em: Oxford University Press 2018
Assuntos:
Abstracts
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6217633/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy148.973
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados